Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.
Stocks · News reference
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Aytu BioPharma reported a Q4 loss of $0.05 per share, beating consensus estimates of -$0.22 loss, representing a 77.27% earnings surprise. The company posted revenues of $16.11 million, surpassing consensus by 39.45%. However, the stock has underperformed the market, down 18.3% year-to-date versus the S&P 500's 13.4% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call
On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time